Clinical Trials Sponsored by National Cancer Institute, Egypt

Total 22120 results

National Cancer Institute (NCI)

Active, not recruiting

NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data

Cancer | Mortality | Chronic Diseases

United States
National Cancer Institute (NCI)

Active, not recruiting

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Uterine Cervical Neoplasms | Small Cell Lung Carcinoma | Ovarian Neoplasms | Carcinoma, Neuroendocrine | Extrapulmonary Small Cell Cancer | Carcinoma, Non-Small -Cell Lung

United States
National Cancer Institute (NCI)

Completed

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Desmoid Tumors | Aggressive Fibromatosis

United States
National Cancer Institute (NCI)

Active, not recruiting

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

Kaposi Sarcoma | Primary Effusion Lymphoma | KSHV Associated Multicentric Castleman Disease | IL-6 Related KSHV Associated Cytokine Syndrome

United States
National Cancer Institute (NCI)

Completed

Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

Melanoma | Skin Cancer | Basal Cell Carcinoma | Squamous Cell Carcinoma | Xeroderma Pigmentosum

United States
National Cancer Institute (NCI)

Completed

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Urinary Bladder Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Gastric Cancer | Gastric Adenocarcinoma | Peritoneal Carcinomatosis | Esophagogastric Junction

United States
National Cancer Institute (NCI)

Enrolling by invitation

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Melanoma | Pancreatic Cancer | Lung Cancer | Solid Tumors | Gastrointestinal Cancer | Hematologic Malignancy | Liver Cancer | Pre-Malignancy

United States
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Sarcoma, Alveolar Soft Part

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | HPV Cancers | Vulvar, Vaginal, Penile, Rectal Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell

United States
National Cancer Institute (NCI)

Completed

Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)

Neurofibromatosis 1 | Peripheral Nerve Neoplasms, Malignant

United States
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
National Cancer Institute (NCI)

Completed

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Biliary Cancer

United States
National Cancer Institute (NCI)

Completed

Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

Melanoma | Lymphoma | Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

M7824 in Subjects With HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Human Papilloma Virus | Vaginal or Penile Cancer

United States
National Cancer Institute (NCI)

Completed

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Pancreatic Cancer | Cholangiocarcinoma | Colon Cancer | Liver Metastasis | Metastatic Colon Carcinoma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell, Peripheral | Lymphoma, Large-Cell, Anaplastic | Lymphoma, Extranodal NK-T-Cell | Enteropathy-Associated T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s

Neuroendocrine Tumors | Carcinoma, Neuroendocrine

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Adrenocortical Carcinoma | Adrenocortical Cancer

United States
National Cancer Institute (NCI)

Completed

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Sarcoma, Kaposi | Kaposi Sarcoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib for Advanced Urothelial Cancer

Kidney Neoplasms | Urinary Bladder Neoplasms | Urothelial Carcinoma | Urethral Neoplasms

United States
National Cancer Institute (NCI)

Completed

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Pazopanib and ARQ 197 for Advanced Solid Tumors

Solid Tumor

United States
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Bevacizumab for Recurrent Ependymoma

Ependymoma | Anaplastic Ependymoma

United States
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
National Cancer Institute (NCI)

Terminated

Sunitinib in Sarcomas of the Central Nervous System

Gliosarcoma | Central Nervous System Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma | Rhabdomyosarcoma, Alveolar | Rhabdomyosarcoma, Embryonal

United States
National Cancer Institute (NCI)

Terminated

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Carcinoma, Renal Cell | Gastrointestinal Stromal Tumors | Pheochromocytoma | Paraganglioma | Renal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Urothelial Cancer

United States
National Cancer Institute (NCI)

Terminated

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

Papillomavirus Infections | Oropharyngeal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Melanoma | Sarcoma | Thoracic Sarcomas | Thorasic Cancers | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer | Gallbladder Cancer

United States
National Cancer Institute (NCI)

Terminated

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Mesothelioma

United States
National Cancer Institute (NCI)

Completed

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

BRCA1 Gene | BRCA2 Gene

United States
National Cancer Institute (NCI)

Terminated

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Anal Cancer

United States
National Cancer Institute (NCI)

Completed

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Subcutaneous Panniculitis-Like T-Cell Lymphoma | T-Cell Peripheral Lymphoma | Gamma Delta Hepatosplenic T-Cell Lymphoma | NK T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

NHS-IL12 for Solid Tumors

Epithelial Tumors, Malignant | Epithelial Neoplasms, Malignant | Malignant Mesenchymal Tumor

United States
National Cancer Institute (NCI)

Terminated

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Hodgkin Disease | Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

Number of Quit Attempts

United States
National Cancer Institute (NCI)

Completed

Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer

Bladder Cancer

United States
National Cancer Institute (NCI)

Terminated

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Cancer | Cancer of Pancreas

United States
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Completed

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Melanoma | Breast Cancer | Non-Small Cell Lung Cancer | Meningioma | Hepatocellular Cancer

United States
National Cancer Institute (NCI)

Completed

Risk Factors for Non-HIV-Related Kaposi s Sarcoma

Kaposi's Sarcoma

Italy

Clinical Trials Sponsored by National Cancer Institute, Egypt

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations